IFN-γ administration has been proposed to improve the efficacy of PD-1 blockade therapy in pancreatic cancer (73) and is under clinical evaluation (e.g., ClinicalTrials.gov NCT02614456, NCT03063632). The gene discussed is PDCD1; the disease is familial pancreatic carcinoma.